Skip to content
Back to meeting Original
METCrusaders· @metcrusaders · X·· 2 days agoScore70
Body

Thanks for laying out the numbers, @HHorinouchi. The 70% vs. 53% one-year overall survival stands out for MET patients. #lcsm #ESMO26

10 views · 0 likes · 0 reposts · 0 replies

引用@
🔥SAFFRON: Osimertinib + savolitinib vs platinum-pemetrexed in EGFR-mutated NSCLC with MET overexpression/amp post-osimertinib 🆙 @NEJM #ESMO26 ☑Phase 3 RCT; N=338; 12-mo PFS 36 vs 10% (HR 0.55, p<0.001); 12-mo OS 70 vs 53% (HR 0.68, p=0.01) 🎙Dr. Shun Lu @nicogirardcurie #LCSM @OncoAlert @Larvol @EGFRResisters @metcrusaders https://www.nejm.org/doi/full/10.1056/NEJMoa2611335
在 X 查看被引用的帖子

Source: METCrusaders · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.